Cryo-Cell International Inc. CCEL
4.24
0.21
5.21%
as of 25 Sep
- Market cap
- $32.5M
- P/E
- 0.0×
Follow CCEL
| Older periods | Aug '25 | Nov '25 | Feb '26 | May '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.20 | 1.02 | 0.84 | 0.92 | |
P/FCF ratio |
7.87 | 8.24 | 7.36 | 6.16 | |
P/Operating CF |
14.99 | 25.07 | 40.54 | 15.49 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.46 | 1.24 | 1.06 | 1.13 | |
EV/EBITDA |
8.07 | 20.99 | 21.01 | 27.30 | |
EV/Operating CF |
7.27 | 7.17 | 6.42 | 5.56 | |
EV/FCF |
9.57 | 10.08 | 9.26 | 7.56 | |
Quick Ratio |
0.54 | 0.51 | 0.55 | 0.63 | |
Current Ratio |
0.63 | 0.59 | 0.62 | 0.71 | |
Net Debt/EBITDA |
3.62 | (1.98) | 6.14 | 3.18 | |
Debt/Assets |
18.06% | 16.96% | 15.98% | 13.31% | |
Debt/Equity |
(0.77) | (0.56) | (0.53) | (0.46) | |
Asset Turnover |
0.50 | 0.50 | 0.50 | 0.50 | |
Operating CF/Net income |
3.39 | (0.34) | 13.84 | 3.33 | |
Capex/Depreciation |
(0.11) | (0.20) | (0.19) | (0.09) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.79% | 1.08% | 0.86% | 1.28% | |
Selling, General and Administrative Expense of Revenue |
49.53% | 69.47% | 65.23% | 59.39% | |
Intangible Assets out of Total Assets |
0.04 | 0.05 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(1.74) | (2.14) | (2.58) | (2.35) | |
Graham Number |
1.70 | 4.01 | 4.14 | 3.88 | |
Earnings Yield |
(1.48%) | (7.79%) | (10.19%) | (8.57%) | |
Free Cash Flow Yield |
12.70% | 12.13% | 13.58% | 16.23% | |
Revenue per Share |
0.97 | 0.97 | 0.95 | 0.97 | |
Operating CF per Share |
0.31 | 0.16 | 0.08 | 0.23 | |
Capex per Share |
0.00 | (0.01) | (0.01) | 0.00 | |
Free Cash Flow per Share |
0.31 | 0.15 | 0.07 | 0.23 | |
Cash per Share |
0.40 | 0.41 | 0.36 | 0.39 | |
Shareholders Equity per Share |
(1.84) | (2.31) | (2.28) | (2.20) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.84) | (2.31) | (2.28) | (2.20) | |
Free Cash Flow |
2.50 | 1.21 | 0.58 | 1.81 | |
Working Capital |
(6.78) | (8.03) | (6.69) | (4.63) | |
Capital Expenditures |
(0.04) | (0.07) | (0.07) | (0.03) | |
Net Current Asset Value |
(66.33) | (68.58) | (68.21) | (67.16) | |
EV/EBIT |
10.68 | 81.46 | 173.71 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.00 | |
Net Profit Margin |
9.58% | (48.67%) | 0.61% | 7.13% | |
Price to Operating Income |
8.79 | 66.58 | 138.04 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.85 | 7.08 | 7.01 | 6.92 | |
Average Payables |
2.31 | 2.38 | 3.02 | 2.54 | |
Average Inventory |
0.69 | 0.53 | 0.54 | 0.49 | |
Average Assets |
63.05 | 63.20 | 62.63 | 62.57 | |
Average Common Equity |
(12.20) | (15.91) | (16.53) | (16.66) |
Columns are period end dates